Crispr Therapeutics AG (CRSP) stock has gained 130.32% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives CRSP stock a score of 67 out of a possible 100.

That rank is mainly influenced by a long-term technical score of 96. CRSP's rank also includes a short-term technical score of 94. The fundamental score for CRSP is 11. In addition to the average rating from Wall Street analysts, CRSP stock has a mean target price of 134. This means analysts expect the stock to fall 12.29% over the next 12 months.

Overall Score - 67
CRSP has an Overall Score of 67. Find out what this means to you and get the rest of the rankings on CRSP!

What's Happening with CRSP Stock Today

Crispr Therapeutics AG (CRSP) stock has gained 2.94% while the S&P 500 has fallen -0.03% as of 3:17 PM on Monday, Dec 14. CRSP has gained $4.36 from the previous closing price of $148.41 on volume of 1,596,118 shares. Over the past year the S&P 500 is up 14.76% while CRSP has gained 130.32%. CRSP lost -$3.25 per share in the over the last 12 months.

Click Here to get the full Stock Score Report on Crispr Therapeutics AG (CRSP) Stock.

Source link